Namodenoson - Can-Fite Biopharma

Drug Profile

Namodenoson - Can-Fite Biopharma

Alternative Names: CF-102; Cl-IB-MECA; Namodenoson

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Can-Fite BioPharma; Rabin Medical Center; Temple University School of Medicine
  • Class Amides; Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Iodobenzenes; Purine nucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Preclinical Colorectal cancer; Hepatic fibrosis; Malignant melanoma; Prostate cancer; Reperfusion injury
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 06 Aug 2018 Namodenoson licensed to CMS Medical in China, Hong Kong, Macao and Taiwan
  • 24 Jun 2018 Biomarkers information updated
  • 11 Jun 2018 Pharmacodynamics data from a preclinical studies in Non-alcoholic steatohepatitis released by Can Fite BioPharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top